Evaluación de herramientas diagnósticas de cardiotoxicidad en pacientes tratados con quimioterapia

Vista sencilla de ítem
dc.contributor.advisorMéndez Toro, Arnold
dc.contributor.advisorTejada, Rafael
dc.contributor.authorMuñoz Rossi, Felipe Alejandro
dc.contributor.datamanagerRojas Ruiz, Ingrid Tatiana
dc.date.accessioned2021-07-07T19:05:12Z
dc.date.available2021-07-07T19:05:12Z
dc.date.issued2020
dc.descriptionilustraciones, tablasspa
dc.description.abstractEl cáncer es un evento en salud catastrófico, siendo actualmente la segunda causa de muerte en América latina y en Colombia, Por lo tanto, es un problema de salud pública que no debe pasar desapercibido. Como parte de los efectos colaterales del tratamiento contra el cáncer, uno de los que presenta mayores repercusiones es el desarrollo de eventos cardiovasculares aumentando la morbimortalidad en los pacientes con cáncer. Dada la relevancia de la cardiotoxicidad, es importante identificarla y efectuar el control de la presencia de esta en los pacientes con quimioterapia, lo cual ha llevado al desarrollo de programas que mediante un abordaje estructurado que congrega a varias especialidades con el fin de categorizar según el perfil de riesgo individualizado una serie de estrategias diagnósticas preventivas y terapéuticas que permitan minimizar el daño derivado de la terapia antineoplásica. De acuerdo con lo anterior, el objetivo del estudio es evaluar el uso de herramientas diagnósticas para la vigilancia de la aparición de cardiotoxicidad en una población adulta con cáncer, bajo tratamiento antineoplásico clasificado como de riesgo intermedio, alto o muy alto de acuerdo a la clasificación de Mayo Clinic Cardiotoxicity Risk, en el Hospital Universitario Nacional de Colombia atendidos entre los años 2016 y 2019. (Texto tomado de la fuente)spa
dc.description.abstractCancer is a catastrophic health event, being currently the second cause of death in Latin America and Colombia. Therefore, it is a public health problem that should not go unnoticed. As part of the collateral effects of cancer treatment, one of those with the greatest repercussions is the development of cardiovascular events, increasing morbidity and mortality in cancer patients. Given the relevance of cardiotoxicity, it is important to identify it and control its presence in patients with chemotherapy, which has led to the development of programs that, through a structured approach that brings together several specialties in order to categorize according to the individualized risk profile a series of preventive and therapeutic diagnostic strategies that allow minimizing the damage derived from antineoplastic therapy. In accordance with the above, the objective of the study is to evaluate the use of diagnostic tools for the surveillance of the appearance of cardiotoxicity in an adult population with cancer, under antineoplastic treatment classified as intermediate, high or very high risk according to the classification from Mayo Clinic Cardiotoxicity Risk, at the National University Hospital of Colombia attended between 2016 and 2019. (Text taken from source)eng
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Medicina internaspa
dc.format.extent76 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/79768
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Medicina Internaspa
dc.publisher.facultyFacultad de Administraciónspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Medicina Internaspa
dc.relation.references1. INC-Instituto Nacional de Cancerología. Atlas de Mortalidad [Internet]. Bogotá; 2017. Available from: cancer.gov.co/ATLAS_de_Mortalidad_por_cancer_en_Colombia.pdfspa
dc.relation.references2. Jaramillo, N. Gónzalez, M., Berrouet, M.C. & Velasquez C. Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Rev Col Card. 2016;23(2):104–11.spa
dc.relation.references3. Curigliano, G., Cardinale, D., Dent, S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25.spa
dc.relation.references4. P. Spallarossa, N. Maurea, C. Cadeddu et al. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17:84–92.spa
dc.relation.references5. N. Maurea, P. Spallarossa, C. Cadeddu et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17:93–104.spa
dc.relation.references6. R. Madonna, C. Cadeddu, M. Deidda et al. Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. Int J Cardiol. 2015;191:203–10.spa
dc.relation.references7. Z.V. Varga, Z. Giricz, P. Bencsik et al. Functional genomics of cardioprotection by ischemic conditioning and the influence of comorbid conditions: Implications in target identification. Curr Drug Targets. 2015;16:904–11.spa
dc.relation.references8. López-Fernández, T., Saura, D., Rodríguez-Palomares, J., Aguadé-Bruix, S., Pérez de Isla, L. & Barba-Cosials J. Cardiac imaging 2015: A selection of topical issues. Rev Esp Cardiol. 2016;69:286–93.spa
dc.relation.references9. J.C. Plana, M. Galderisi, A. Barac et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr,. 2014;27:911–39.spa
dc.relation.references10. Madonna R. Diagnóstico y prevención de la cardiotoxicidad inducida por fármacos antineoplásicos: de la imagen a las tecnologías «ómicas». Rev Esp Cardiol. 2017;70(7):576–82.spa
dc.relation.references11. World Health Organization. Globocan 2012: Estimated Cancer incidence, mortality and prevalence worldwide. Lyon; 2012.spa
dc.relation.references12. Florescu, M., Cinteza, M. & Vinereanu D. Chemotherapy-induced Cardiotoxicity. Mædica. 2013;8(1):59–67.spa
dc.relation.references13. Figueredo, V.M. & Chemical C. The Negative Effects of Medications and Nonprescribed Drugs on the Heart. Am J Med. 2011;124(6):480–8.spa
dc.relation.references14. DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D. K, J.L. et al. Cancer treatment and survivorship statistics, 2014: Cancer Treatment and Survivorship Statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.spa
dc.relation.references15. Ruiz, E., Ayala, L., Burgos J. Insuficiencia Cardiaca por quimioterapia. Rev Soc Per Med Int. 2016;29(2):59–64.spa
dc.relation.references16. Perrino, C., Schiattarella, G., Magliulo, F., Ilardi, F., Carotenuto, G., Gargiulo, G. et al. Cardiac side effects of chemotherapy: state of art and strategies for a correct management. Curr Vasc Pharm. 2014;12(1):106–16.spa
dc.relation.references17. Bloom, M., Hamo, C., Cardinale, D., Ky, B., Nohria, A., Baer, L. E, Al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Circ Hear Fail. 2016;9(2):e002843.spa
dc.relation.references18. Bovelli, D., Plataniotis, G., Roila, F. O behalf of the EGWG. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Supplement 5):277–82.spa
dc.relation.references19. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.spa
dc.relation.references20. Jiji, R.S., Kramer CM& SM. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol Off Publ Am Soc Nucl Cardiol. 2012;19(2):377–88.spa
dc.relation.references21. Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora S&, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25.spa
dc.relation.references22. Siegel, R.L., Miller, K.D. & Jemal A. Cancer statistics, 2015: Cancer Statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.spa
dc.relation.references23. Ministerio de Salud P. Análisis de la situación del cáncer en el Perú 2013. Lima; 2013.spa
dc.relation.references24. Minsalud. Observatorio Nacional de Cáncer [Internet]. Dirección de Epidemiología y Prevención. D de P y P& S de E no T, editor. Bogotá: Minsalud; 2018. 9–10 p. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/GCFI/guia-ross-cancer.pdfspa
dc.relation.references25. Virizuela JA, García AM, de las Peñas R, Santaballa A, Andrés R, Beato C, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin Transl Oncol. 2019;21(1):94–105.spa
dc.relation.references26. Alvarez JA, Russell RR. Cardio-oncology: the Nuclear Option. Vol. 19, Current Cardiology Reports. Current Medicine Group LLC 1; 2017.spa
dc.relation.references27. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768–801.spa
dc.relation.references28. Tamargo J, Caballero R, Delpón E. Cancer Chemotherapy and Cardiac Arrhythmias: A Review. Vol. 38, Drug Safety. Springer International Publishing; 2015. p. 129–52.spa
dc.relation.references29. Kappel C, Rushton M, Johnson C, Aseyev O, Small G, Law A, et al. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: An observational cohort study. Curr Oncol. 2019;26(3):e322–7.spa
dc.relation.references30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar;344(11):783–92.spa
dc.relation.references31. Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clin Med Insights Cardiol. 2019 Jan;13:117954681986644.spa
dc.relation.references32. Zhang X, Zhu Y, Dong S, Zhang A, Lu Y, Li Y, et al. Role of oxidative stress in cardiotoxicity of antineoplastic drugs. Vol. 232, Life Sciences. Elsevier Inc.; 2019.spa
dc.relation.references33. Almuwaqqat Z, Meisel JL, Barac A, Parashar S. Breast Cancer and Heart Failure. Vol. 15, Heart Failure Clinics. Elsevier Inc.; 2019. p. 65–75.spa
dc.relation.references34. Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39(2):168–74.spa
dc.relation.references35. Accordino MK, Neugut AI, Hershman DL. Cardiac effects of anticancer therapy in the elderly. Vol. 32, Journal of Clinical Oncology. American Society of Clinical Oncology; 2014. p. 2654–61.spa
dc.relation.references36. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003 Jun;97(11):2869–79.spa
dc.relation.references37. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol Educ B. 2018 May;(38):3–12.spa
dc.relation.references38. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 Sep;266(12):1672–7.spa
dc.relation.references39. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015 Jun;131(22):1981–8.spa
dc.relation.references40. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: Cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306.spa
dc.relation.references41. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9(7):1215–23.spa
dc.relation.references42. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981 May;141(6):758–63.spa
dc.relation.references43. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72–80.spa
dc.relation.references44. Sendur MAN, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Vol. 29, Current Medical Research and Opinion. 2013. p. 1015–24.spa
dc.relation.references45. Dokmanovic M, King KE, Mohan N, Endo Y, Wu WJ. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab. Vol. 13, Expert Opinion on Drug Metabolism and Toxicology. Taylor and Francis Ltd; 2017. p. 755–66.spa
dc.relation.references46. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Vol. 12, Nature Reviews Cardiology. Nature Publishing Group; 2015. p. 547–58.spa
dc.relation.references47. Onitilo AA, Engel JM, Stankowski R V. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: Prevalence, patient characteristics, and risk factors. Vol. 5, Therapeutic Advances in Drug Safety. 2014. p. 154–66.spa
dc.relation.references48. Armenian SH, Lacchetti C, Barac A. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 35:893–911.spa
dc.relation.references49. Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Preventive strategies and cardiovascular surveillance. Vol. 13, Vascular Health and Risk Management. Dove Medical Press Ltd.; 2017. p. 293–303.spa
dc.relation.references50. Lee WS, Kim J. Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy. Vol. 14, Molecular and Cellular Toxicology. Springer Verlag; 2018. p. 247–54.spa
dc.relation.references51. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137(11):1176–91.spa
dc.relation.references52. Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J. Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Vol. 16, Current Treatment Options in Cardiovascular Medicine. Springer Healthcare; 2014.spa
dc.relation.references53. Cole DC, Frishman WH. Cardiovascular complications of proteasome inhibitors used in multiple myeloma. Vol. 26, Cardiology in Review. Lippincott Williams and Wilkins; 2018. p. 122–9.spa
dc.relation.references54. Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J Community Hosp Intern Med Perspect. 2015 Jan;5(6):28982.spa
dc.relation.references55. Reneau JC, Asante D, van Houten H, Sangaralingham LR, Buadi FK, Lerman A, et al. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients. Vol. 92, American Journal of Hematology. Wiley-Liss Inc.; 2017. p. E15–7.spa
dc.relation.references56. Chow EJ, Chen Y, Kremer LC, Breslow NE, Hudson MM, Armstrong GT, et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2015 Feb;33(5):394–402.spa
dc.relation.references57. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014 Feb;3(1):e000472.spa
dc.relation.references58. Cardinale DM, Barac A, Torbicki A, Khandheria BK, Lenihan D, Minotti G. Cardio-oncological management of patients. Semin Oncol. 2019 Dec;46(6):408–13.spa
dc.relation.references59. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur J Cancer. 2018 May;94:126–37.spa
dc.relation.references60. Advani PP, Ballman K V, Dockter TJ, Colon-Otero G, Perez EA. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 2016 Feb;34(6):581–7.spa
dc.relation.references61. Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep;25(25):3859–65.spa
dc.relation.references62. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010 Sep;28(25):3910–6.spa
dc.relation.references63. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A MT. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review - PubMed. J Am Coll Cardiol. 2014;1(63):2751–8. 64. Kenigsberg B, Wellstein A, Barac A. Left Ventricular Dysfunction in Cancer Treatment. JACC Hear Fail. 2018;6(2).spa
dc.relation.references65. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. J Am Coll Cardiol HF. 1:72–8.spa
dc.relation.references66. Boffa RJ, Constanti M, Floyd CN, Wierzbicki AS. Hypertension in adults: Summary of updated NICE guidance. BMJ. 2019;367(October):1–6.spa
dc.relation.references67. Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F. Arterial hypertension and cancer. Vol. 134, International Journal of Cancer. Wiley-Liss Inc.; 2014. p. 2269–77.spa
dc.relation.references68. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. Vol. 39, European Heart Journal. Oxford University Press; 2018. p. 3021–104.spa
dc.relation.references69. Schlitt A, Jordan K, Vordermark K, Schwamborn J, Langer T TC. Cardiotoxicity and oncological treatments. Dtsch Ärztebl Int. 2014;111:161–8.spa
dc.relation.references70. Reagan WJ, York M, Berridge B, Schultze E, Walker D PS. Comparison of Cardiac Troponin I and T, Including the Evaluation of an Ultrasensitive Assay, as Indicators of Doxorubicin-induced Cardiotoxicity. Toxicol Pathol. 2013;41:1146–58.spa
dc.relation.references71. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T TM. Troponins and Brain Natriuretic Peptides for the Prediction of Cardiotoxicity in Cancer Patients: A Meta-Analysis. Eur J Hear Fail. 2020;22(2):350–61.spa
dc.relation.references72. Velasquez CA, González M, Berrouet MC JN. Cardiotoxicidad inducida por la quimioterapia desde las bases moleculares hasta la perspectiva clínica. Rev Col Card. 2016;23(3):104–11.spa
dc.relation.references73. Dogru A, Cabuk D, Sahin T, Dolasik I, Temiz S UK. Evaluation of Cardiotoxicity via Speckle-Tracking Echocardiography in Patients Treated with Anthracyclines. Oncol Res Treat. 2013;36(712–716).spa
dc.relation.references74. Seo JM, Park TH, Lee DY et al. Subclinical myocardial dysfunction in metabolic syndrome patients without hypertension. J Cardiiovasc Ultrasound. 2011;19:134–9.spa
dc.relation.references75. Stanton T, Leano R MT. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2:356–64.spa
dc.relation.references76. Thavendiranathan P, Negishi T, Somerset E, Negishi K et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2020;spa
dc.relation.references77. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P et al. The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the. J Hear Fail. 2020;spa
dc.relation.references78. Ruiz Mori E, Ayala Bustamante L BBJ. Insuficiencia cardíaca por quimioterapia. Rev Soc Per Med Int. 2016;29(2):59–64.spa
dc.relation.references79. Marty M, Cognetti F, Maraninchi D, Snyder R ML. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265.spa
dc.relation.references80. KR. C. Herceptin and the heart a molecular modifier of cardiac failure. NEJM. 2006;354:789–90.spa
dc.relation.references81. Navarrete S, Castellanos A SC. Cardiotoxicidad por quimioterapia: Enfoque práctico para el clínico. Insuf Card. 2011;6(3):131–43.spa
dc.relation.references82. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;105(25):3122.spa
dc.relation.references83. Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA et al. A. Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): e. Circulation. 2005;112(12):1853–67.spa
dc.relation.references84. Yeh ET BC. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.spa
dc.relation.references85. Jiménez-Cotes EA, Meyer-Martínez WS G-GD. Biomarcadores en la detección temprana de cardiotoxicidad inducida por quimioterapia; estado actual. Arch Med. 2015;15(1):126–37.spa
dc.relation.references86. López-Velarde Peña T L-VBP. Prevención y tratamiento de cardiotoxicidad en pacientes con cáncer. An Med. 2014;59(1):54–60.spa
dc.relation.references87. Lax J, Piñeiro D, Falconi M, Agüero R, Barugel M, Bermann A et al. Consenso de diagnóstico, prevención y tratamiento de la cardiotoxicidad por tratamiento médico del cáncer. Rev Arg Cardiol. 2013;81(5):1–64.spa
dc.relation.references88. Reborido N, Parma G, Noria S, Schiavone A, Bonelli A LR. Strain bidimensional para detección precoz de disfunción sistólica del ventrículo izquierdo inducida por agentes quimioterápicos. Rev Urug Card. 2016;31(2):266–76.spa
dc.relation.references89. Navarro-Ulloa OD, Barranco-Camargo LA, Jurado-López SP, Zabala-Carballo CI G-P LE. Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas. Rev Col Card. 2018;25(1):1–7.spa
dc.relation.references90. Gutiérrez-Alba G, González-Block MÁ R-MH. Desafíos en la implantación de guías de práctica clínica en instituciones públicas de México: estudio de casos múltiple. Sal Pub Mex. 2015;57(6):547–54.spa
dc.relation.references91. Kenefick H, Lee J F V. Improving physician adherence to clinical practice guidelines barriers and strategies for change. New Engl Heal Inst. 2008;55.spa
dc.relation.references92. Constantino-Casas P, Medécigo-Micete C, Millán-Gámez YYK, Torres-Arreola LDPL, Valenzuela-Flores AA, Viniegra-Osorio A et al. Survey on physicians’ knowledge and attitudes towards clinical practice guidelines at the Mexican Institute of Social Security. Eval Clin Pr. 2011;17(4):768–74.spa
dc.rightsDerechos Reservados al Autor, 2021spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/spa
dc.subject.ddc610 - Medicina y saludspa
dc.subject.decsDrug-Related Side Effects and Adverse Reactions
dc.subject.decsEfectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
dc.subject.decsQuimioterapia
dc.subject.decsChemotherapy
dc.subject.proposalCardiotoxicidadspa
dc.subject.proposalCáncerspa
dc.subject.proposalAntraciclinasspa
dc.subject.proposalCardiotoxicityeng
dc.subject.proposalCancereng
dc.subject.proposalAnthracyclineseng
dc.titleEvaluación de herramientas diagnósticas de cardiotoxicidad en pacientes tratados con quimioterapiaspa
dc.title.translatedEvaluation of diagnostic tools for cardiotoxicity in patients treated with chemotherapyeng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_46ecspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audienceGeneralspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
72292127.2021.pdf
Tamaño:
2.27 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad en Medicina Interna
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
3.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialidad en Medicina Interna